| Technical Name | BPRSJ338: Therapeutic Applications for COVID-19 | ||
|---|---|---|---|
| Project Operator | National Health Research Institutes | ||
| Project Host | 李秀珠 | ||
| Summary | BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted. Therefore it is also applicable to fight against severe evolving coronaviruses in the future. |
||
| Scientific Breakthrough | BPRSJ338 is an inhibitor effectively against broad-spectrum coronaviruses. It exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19. BPRSJ338 targets the RNP complex containing viral RNA and nucleoprotein to block replication of coronaviruses including human coronavirus SARS-CoV, SARS-CoV-2, HCoV-229E, HCoV-OC43 as well as FIPV, TGEV and MHV. Related US and Taiwan patents have been granted. Strikingly, BPRSJ338 exhibits a greater inhibitory activity (~50 to ~80 folds) against coronaviruses e.g. SARS-CoV-2, HCOV-OC43, than remdesivir . |
||
| Industrial Applicability | Up to date, there is no effective vaccine or drug treatment for coronaviruses yet. BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Therefore it is also applicable to fight against COVID-19 and other severe evolving coronaviruses in the future. |
||
| Matching Needs | - |
||
| Keyword | Plant derived new drugs RNA virus SARS-CoV-2 Small molecule drug New drug discovery Clinical pharmaceutics Coronavirus COVID-19 pandemic virus | ||
| Notes | |||
- Contact
- enachen@nhri.edu.tw
other people also saw
